Massimiliano Rampazzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Massimiliano Rampazzo has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Abhishek Singh
Janssen Pharmaceutica NV, 2340 Beerse, Belgium
1 shared publication - Filip Vanhoutte
Janssen Pharmaceutica, Turnhoutseweg 30, 2340 Beerse, Belgium
1 shared publication - Guy Van Den Mooter
Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven 3000, Belgium
1 shared publication - Piyush Panini
Department of Pharmaceutical and Pharmacological Sciences, Drug Delivery and Disposition, KU Leuven, 3000 Leuven, Belgium
1 shared publication
Latest Publications
- Open Access
- 14 October 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (10) , 529
Myth or Truth: The Glass Forming Ability Class III Drugs Will Always Form Single-Phase Homogenous Amorphous Solid Dispersion Formulations
The physical stability of amorphous solid dispersions (ASD) of active pharmaceutical ingredients (APIs) of high glass forming ability (GFA class III) is generally expected to be high among the scientific community. In this study, the ASD of ten-selected class III APIs with the two polymers, PVPVA 64 and HPMC-E5, have been prepared by spray-drying, film-casting, and their amorphicity at T0 was investigated by modulated differential scanning calorimetry and powder X-ray diffraction. It was witnessed that only five out of ten APIs form good quality amorphous solid dispersions with no phase separation and zero crystalline content, immediately after the preparation and drying process. Hence, it was further established that the classification of an API as GFA class III does not guarantee the formulation of single phase amorphous solid dispersions.
- 14 October 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (10) , 529
Open AccessMyth or Truth: The Glass Forming Ability Class III Drugs Will Always Form Single-Phase Homogenous Amorphous Solid Dispersion Formulations
The physical stability of amorphous solid dispersions (ASD) of active pharmaceutical ingredients (APIs) of high glass forming ability (GFA class III) is generally expected to be high among the scientific community. In this study, the ASD of ten-selected class III APIs with the two polymers, PVPVA 64 and HPMC-E5, have been prepared by spray-drying, film-casting, and their amorphicity at T0 was investigated by modulated differential scanning calorimetry and powder X-ray diffraction. It was witnessed that only five out of ten APIs form good quality amorphous solid dispersions with no phase separation and zero crystalline content, immediately after the preparation and drying process. Hence, it was further established that the classification of an API as GFA class III does not guarantee the formulation of single phase amorphous solid dispersions.